Pharming Group NV (PHAR)
9.68
-0.12
(-1.22%)
USD |
NASDAQ |
Oct 06, 16:00
Pharming Group Enterprise Value : 653.60M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 653.60M |
| October 05, 2026 | 662.10M |
| October 02, 2026 | 658.56M |
| October 01, 2026 | 672.71M |
| September 30, 2026 | 675.55M |
| September 29, 2026 | 676.96M |
| September 28, 2026 | 713.06M |
| September 25, 2026 | 708.81M |
| September 24, 2026 | 707.40M |
| September 23, 2026 | 730.75M |
| September 22, 2026 | 765.43M |
| September 21, 2026 | 733.58M |
| September 18, 2026 | 715.18M |
| September 17, 2026 | 731.46M |
| September 16, 2026 | 718.72M |
| September 15, 2026 | 715.18M |
| September 14, 2026 | 734.29M |
| September 11, 2026 | 761.89M |
| September 10, 2026 | 733.23M |
| September 09, 2026 | 744.91M |
| September 08, 2026 | 782.42M |
| September 04, 2026 | 763.31M |
| September 03, 2026 | 779.59M |
| September 02, 2026 | 761.19M |
| September 01, 2026 | 754.82M |
| Date | Value |
|---|---|
| August 31, 2026 | 781.00M |
| August 28, 2026 | 796.58M |
| August 27, 2026 | 802.24M |
| August 26, 2026 | 814.27M |
| August 25, 2026 | 801.53M |
| August 24, 2026 | 779.59M |
| August 21, 2026 | 807.19M |
| August 20, 2026 | 795.16M |
| August 19, 2026 | 807.19M |
| August 18, 2026 | 811.44M |
| August 17, 2026 | 802.95M |
| August 14, 2026 | 797.99M |
| August 13, 2026 | 842.58M |
| August 12, 2026 | 805.78M |
| August 11, 2026 | 834.09M |
| August 10, 2026 | 771.80M |
| August 07, 2026 | 743.49M |
| August 06, 2026 | 736.41M |
| August 05, 2026 | 724.03M |
| August 04, 2026 | 694.66M |
| August 03, 2026 | 663.51M |
| July 31, 2026 | 681.92M |
| July 30, 2026 | 729.34M |
| July 29, 2026 | 818.52M |
| July 28, 2026 | 878.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProQR Therapeutics NV | 114.03M |
| NewAmsterdam Pharma Co. NV | 1.985B |
| argenx SE | 57.52B |
| Nektar Therapeutics | 813.71M |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.598M |
| Revenue (Quarterly) | 90.08M |
| Total Expenses (Quarterly) | 88.48M |
| EPS Diluted (Quarterly) | 0.02 |
| Gross Profit Margin (Quarterly) | 80.56% |
| Profit Margin (Quarterly) | 1.77% |
| Earnings Yield | 1.28% |
| Operating Earnings Yield | 3.14% |
| Normalized Earnings Yield | 2.302 |